Drugs / vaccinia-tyrosinase vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00054535 | Jan 2003 → Sep 2004 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00019734 | Jul 1999 → May 2003 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vaccinia-tyrosinase vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00019734 ↗ |
| Known as | recombinant vaccinia vaccine | “Arm I: Patients receive recombinant fowlpox vaccine IM on day 1 followed 4 weeks later by recombinant vaccinia vaccine IM.” NCT00019734 ↗ |
| Modality | Vaccine | “recombinant vaccinia vaccine IM” NCT00019734 ↗ |
| Route | Intramuscular | “recombinant vaccinia vaccine IM” NCT00019734 ↗ |